Mydecine Innovations Group Inc.
MYCO
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 25.16% | -158.89% | 88.52% | -644.17% | 52.96% |
| Total Depreciation and Amortization | -- | -- | -- | -100.00% | -64.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.29% | 3.74% | -94.77% | 2,518.02% | 2.43% |
| Change in Net Operating Assets | -27.99% | 245.60% | -79.79% | 255.46% | -37.32% |
| Cash from Operations | 795.92% | 61.72% | -101.83% | 3,986.67% | 97.05% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | -- | -- | -- | -- | -100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -99.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -97,914.29% | -99.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 795.92% | 61.72% | -185.91% | 186.63% | -176.44% |
